30 results on '"Talos DM"'
Search Results
2. Hyperactive neuronal networks facilitate tau spread in an Alzheimer's disease mouse model.
- Author
-
Barbour AJ, Hoag K, Cornblath EJ, Chavez A, Lucas A, Li X, Zebrowitz S, Hassman C, Lee EB, Davis KA, Lee VMY, Talos DM, and Jensen FE
- Abstract
Pathological tau spreads throughout the brain along neuronal connections in Alzheimer's disease (AD), but the mechanisms that underlie this process are poorly understood. Given the high incidence and deleterious consequences of epileptiform activity in AD, we hypothesized neuronal hyperactivity and seizures are key factors in tau spread. To examine these interactions, we created a novel mouse model involving the cross of targeted recombination in active populations (TRAP) mice and the 5 times familial AD (5XFAD; 5X-TRAP) model allowing for the permanent fluorescent labelling of neuronal activity. To establish a causal role of seizures in tau spread, we seeded mice with human AD brain-derived tau lysate and induced seizures with pentylenetetrazol (PTZ) kindling. Comprehensive brain mapping of tau pathology and neuronal activity revealed that basal hyperactivity in 5X-TRAP mice was associated with increased tau spread, which was exacerbated by seizure induction through activated networks and correlated with memory deficits. Computational modeling revealed that anterograde tau spread was elevated in 5X-TRAP mice and that regional neuronal activity was predictive of tau spread to that brain region. On a cellular level, we found that in both saline and PTZ-treated 5X-TRAP mice, hyperactive neurons disproportionately contributed to the spread of tau. Further, we found that Synaptogyrin-3, a synaptic vesicle protein that interacts with tau, was increased following PTZ kindling in 5X-TRAP mice, possibly indicative of a synaptic mechanism underlying seizure-exacerbated tau spread. Importantly, postmortem AD brain tissue from patients with a history of seizures showed increased tau pathology in patterns indicative of increased spread and increased Synaptogyrin-3 levels compared to those without seizures. Overall, our study identifies neuronal hyperactivity and seizures as key factors underlying the pathobiological and cognitive progression of AD. Therapies targeting these factors should be tested clinically to slow tau spread and AD progression.
- Published
- 2024
- Full Text
- View/download PDF
3. Hyperexcitability precedes CA3 hippocampal neurodegeneration in a dox-regulatable TDP-43 mouse model of ALS-FTD.
- Author
-
Rodemer W, Ra I, Jia E, Gujral J, Zhang B, Hoxha K, Xing B, Mehta S, Farag M, Porta S, Jensen FE, Talos DM, and Lee VM
- Abstract
Neuronal hyperexcitability is a hallmark of amyotrophic lateral sclerosis (ALS) but its relationship with the TDP-43 aggregates that comprise the predominant pathology in over 90% of ALS cases remains unclear. Emerging evidence in tissue and slice culture models indicate that TDP-43 pathology induces neuronal hyperexcitability suggesting it may be responsible for the excitotoxicity long believed to be a major driver of ALS neuron death. Here, we characterized hyperexcitability and neurodegeneration in the hippocampus of doxycycline-regulatable rNLS8 mice (NEFH-tTA x tetO-hTDP-43ΔNLS), followed by treatment with AAV encoded DREADDs and anti-seizure medications to measure the effect on behavioral function and neurodegeneration. We found that approximately half of the CA3 neurons in the dorsal hippocampus are lost between 4 and 6 weeks after TDP-43ΔNLS induction. Neurodegeneration was preceded by selective hyperexcitability in the mossy fiber - CA3 circuit, leading us to hypothesize that glutamate excitotoxicity may be a significant contributor to neurodegeneration in this model. Interestingly, hippocampal injection of AAV encoded inhibitory DREADDs (hM4Di) and daily activation with CNO ligand rescued anxiety deficits on elevated zero maze (EZM) but did not reduce neurodegeneration. Therapeutic doses of the anti-seizure medications, valproic acid and levetiracetam, did not improve behavior or prevent neurodegeneration. These results highlight the complexity of TDP-43 - induced alterations to neuronal excitability and suggest that whereas targeting hyperexcitability can meliorate some behavioral deficits, it may not be sufficient to halt or slow neurodegeneration in TDP-43-related proteinopathies., Significance Statement: Cytoplasmic aggregates of TAR DNA Binding Protein 43 (TDP-43) are the predominant pathology in over 90% of Amyotrophic lateral sclerosis (ALS) and the majority of frontotemporal lobar degeneration (FTLD-TDP) cases. Understanding how TDP-43 pathology promotes neurodegeneration may lead to therapeutic strategies to slow disease progression in humans. Recent reports in mouse and cell culture models suggest loss-of-normal TDP-43 function may drive neuronal hyperexcitability, a key physiological hallmark of ALS and possible contributor to neurodegeneration. In this study, we identified region-specific hyperexcitability that precedes neurodegeneration in the inducible rNLS8 TDP-43 mouse model. Suppressing hyperexcitability with chemogenetics improved behavioral function but did not reduce hippocampal neuron loss. Anti-seizure medications had no beneficial effects suggesting directly targeting hyperexcitability may not be therapeutically effective.
- Published
- 2024
- Full Text
- View/download PDF
4. Seizures exacerbate excitatory: inhibitory imbalance in Alzheimer's disease and 5XFAD mice.
- Author
-
Barbour AJ, Gourmaud S, Lancaster E, Li X, Stewart DA, Hoag KF, Irwin DJ, Talos DM, and Jensen FE
- Subjects
- Animals, Mice, Male, Humans, Female, Pentylenetetrazole toxicity, Aged, Disease Models, Animal, Kindling, Neurologic drug effects, Aged, 80 and over, Alzheimer Disease metabolism, Alzheimer Disease physiopathology, Seizures metabolism, Seizures physiopathology, Mice, Transgenic
- Abstract
Approximately 22% of Alzheimer's disease (AD) patients suffer from seizures, and the co-occurrence of seizures and epileptiform activity exacerbates AD pathology and related cognitive deficits, suggesting that seizures may be a targetable component of AD progression. Given that alterations in neuronal excitatory:inhibitory (E:I) balance occur in epilepsy, we hypothesized that decreased markers of inhibition relative to those of excitation would be present in AD patients. We similarly hypothesized that in 5XFAD mice, the E:I imbalance would progress from an early stage (prodromal) to later symptomatic stages and be further exacerbated by pentylenetetrazol (PTZ) kindling. Post-mortem AD temporal cortical tissues from patients with or without seizure history were examined for changes in several markers of E:I balance, including levels of the inhibitory GABAA receptor, the sodium potassium chloride cotransporter 1 (NKCC1) and potassium chloride cotransporter 2 (KCC2) and the excitatory NMDA and AMPA type glutamate receptors. We performed patch-clamp electrophysiological recordings from CA1 neurons in hippocampal slices and examined the same markers of E:I balance in prodromal 5XFAD mice. We next examined 5XFAD mice at chronic stages, after PTZ or control protocols, and in response to chronic mTORC1 inhibitor rapamycin, administered following kindled seizures, for markers of E:I balance. We found that AD patients with comorbid seizures had worsened cognitive and functional scores and decreased GABAA receptor subunit expression, as well as increased NKCC1/KCC2 ratios, indicative of depolarizing GABA responses. Patch clamp recordings of prodromal 5XFAD CA1 neurons showed increased intrinsic excitability, along with decreased GABAergic inhibitory transmission and altered glutamatergic neurotransmission, indicating that E:I imbalance may occur in early disease stages. Furthermore, seizure induction in prodromal 5XFAD mice led to later dysregulation of NKCC1/KCC2 and a reduction in GluA2 AMPA glutamate receptor subunit expression, indicative of depolarizing GABA receptors and calcium permeable AMPA receptors. Finally, we found that chronic treatment with the mTORC1 inhibitor, rapamycin, at doses we have previously shown to attenuate seizure-induced amyloid-β pathology and cognitive deficits, could also reverse elevations of the NKCC1/KCC2 ratio in these mice. Our data demonstrate novel mechanisms of interaction between AD and epilepsy and indicate that targeting E:I balance, potentially with US Food and Drug Administration-approved mTOR inhibitors, hold therapeutic promise for AD patients with a seizure history., (© The Author(s) 2024. Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.)
- Published
- 2024
- Full Text
- View/download PDF
5. Cannabidiol attenuates seizure susceptibility and behavioural deficits in adult CDKL5 R59X knock-in mice.
- Author
-
Li X, Yennawar M, Wiest A, O'Brien WT, Babrowicz B, White RS, Talos DM, and Jensen FE
- Subjects
- Male, Gene Knock-In Techniques methods, TRPV Cation Channels genetics, TRPV Cation Channels metabolism, Spasms, Infantile, Mice, Inbred C57BL, Pentylenetetrazole, Cerebral Cortex drug effects, Cerebral Cortex metabolism, Receptors, Cannabinoid, Receptor, Cannabinoid, CB1 genetics, Receptor, Cannabinoid, CB1 metabolism, Disease Models, Animal, Endocannabinoids metabolism, Animals, Hippocampus metabolism, Hippocampus drug effects, Mice, Cannabidiol pharmacology, Cannabidiol therapeutic use, Seizures drug therapy, Seizures genetics, Behavior, Animal drug effects, Epileptic Syndromes drug therapy, Epileptic Syndromes genetics, Epileptic Syndromes physiopathology, Protein Serine-Threonine Kinases genetics, Protein Serine-Threonine Kinases metabolism
- Abstract
Cyclin-dependent kinase-like 5 (CDKL5) deficiency disorder (CDD) is caused by a loss-of-function mutation in CDKL5 gene, encoding a serine-threonine kinase highly expressed in the brain. CDD manifests with early-onset epilepsy, autism, motor impairment and severe intellectual disability. While there are no known treatments for CDD, the use of cannabidiol has recently been introduced into clinical practice for neurodevelopmental disorders. Given the increased clinical utilization of cannabidiol, we examined its efficacy in the CDKL5
R59X knock-in (R59X) mice, a CDD model based on a human mutation that exhibits both lifelong seizure susceptibility and behavioural deficits. We found that cannabidiol pre-treatment rescued the increased seizure susceptibility in response to the chemoconvulsant pentylenetetrazol (PTZ), attenuated working memory and long-term memory impairments, and rescued social deficits in adult R59X mice. To elucidate a potential mechanism, we compared the developmental hippocampal and cortical expression of common endocannabinoid (eCB) targets in R59X mice and their wild-type littermates, including cannabinoid type 1 receptor (CB1R), transient receptor potential vanilloid type 1 (TRPV1) and 2 (TRPV2), G-coupled protein receptor 55 (GPR55) and adenosine receptor 1 (A1R). Many of these eCB targets were developmentally regulated in both R59X and wild-type mice. In addition, adult R59X mice demonstrated significantly decreased expression of CB1R and TRPV1 in the hippocampus, and TRPV2 in the cortex, while TRPV1 was increased in the cortex. These findings support the potential for dysregulation of eCB signalling as a plausible mechanism and therapeutic target in CDD, given the efficacy of cannabidiol to attenuate hyperexcitability and behavioural deficits in this disorder., (© 2024 The Authors. European Journal of Neuroscience published by Federation of European Neuroscience Societies and John Wiley & Sons Ltd.)- Published
- 2024
- Full Text
- View/download PDF
6. Reversible synaptic adaptations in a subpopulation of murine hippocampal neurons following early-life seizures.
- Author
-
Xing B, Barbour AJ, Vithayathil J, Li X, Dutko S, Fawcett-Patel J, Lancaster E, Talos DM, and Jensen FE
- Subjects
- Animals, Mice, Neurons, Hippocampus, Receptors, AMPA genetics, Seizures genetics, Adamantane analogs & derivatives
- Abstract
Early-life seizures (ELSs) can cause permanent cognitive deficits and network hyperexcitability, but it is unclear whether ELSs induce persistent changes in specific neuronal populations and whether these changes can be targeted to mitigate network dysfunction. We used the targeted recombination of activated populations (TRAP) approach to genetically label neurons activated by kainate-induced ELSs in immature mice. The ELS-TRAPed neurons were mainly found in hippocampal CA1, remained uniquely susceptible to reactivation by later-life seizures, and displayed sustained enhancement in α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptor-mediated (AMPAR-mediated) excitatory synaptic transmission and inward rectification. ELS-TRAPed neurons, but not non-TRAPed surrounding neurons, exhibited enduring decreases in Gria2 mRNA, responsible for encoding the GluA2 subunit of the AMPARs. This was paralleled by decreased synaptic GluA2 protein expression and heightened phosphorylated GluA2 at Ser880 in dendrites, indicative of GluA2 internalization. Consistent with increased GluA2-lacking AMPARs, ELS-TRAPed neurons showed premature silent synapse depletion, impaired long-term potentiation, and impaired long-term depression. In vivo postseizure treatment with IEM-1460, an inhibitor of GluA2-lacking AMPARs, markedly mitigated ELS-induced changes in TRAPed neurons. These findings show that enduring modifications of AMPARs occur in a subpopulation of ELS-activated neurons, contributing to synaptic dysplasticity and network hyperexcitability, but are reversible with early IEM-1460 intervention.
- Published
- 2024
- Full Text
- View/download PDF
7. Discovery of E2730, a novel selective uncompetitive GAT1 inhibitor, as a candidate for anti-seizure medication.
- Author
-
Fukushima K, Higashiyama H, Kazuta Y, Hashimoto K, Watanabe N, Furuya Y, Ito Y, Wu T, Kosasa T, Talos DM, Song Y, Roberts NS, Jensen FE, Hanada T, and Ido K
- Subjects
- Animals, Humans, Mice, Ataxia, gamma-Aminobutyric Acid pharmacology, gamma-Aminobutyric Acid metabolism, HEK293 Cells, Epilepsy drug therapy, GABA Plasma Membrane Transport Proteins administration & dosage, Anticonvulsants pharmacology, Anticonvulsants therapeutic use
- Abstract
Objective: As of 2022, 36 anti-seizure medications (ASMs) have been licensed for the treatment of epilepsy, however, adverse effects (AEs) are commonly reported. Therefore, ASMs with a wide margin between therapeutic effects and AEs are preferred over ASMs that are associated with a narrow margin between efficacy and risk of AEs. E2730 was discovered using in vivo phenotypic screening and characterized as an uncompetitive, yet selective, inhibitor of γ-aminobutyric acid (GABA) transporter 1 (GAT1). Here, we describe the preclinical characteristics of E2730., Methods: Anti-seizure effects of E2730 were evaluated in several animal models of epilepsy: corneal kindling, 6 Hz-44 mA psychomotor seizure, amygdala kindling, Fragile X syndrome, and Dravet syndrome models. Effects of E2730 on motor coordination were assessed in accelerating rotarod tests. The mechanism of action of E2730 was explored by [
3 H]E2730 binding assay. The GAT1-selectivity over other GABA transporters was examined by GABA uptake assay of GAT1, GAT2, GAT3, or betaine/GABA transporter 1 (BGT-1) stably expressing HEK293 cells. To further investigate the mechanism for E2730-mediated inhibition of GAT1, in vivo microdialysis and in vitro GABA uptake assays were conducted under conditions of different GABA concentrations., Results: E2730 showed anti-seizure effects in the assessed animal models with an approximately >20-fold margin between efficacy and motor incoordination. [3 H]E2730 binding on brain synaptosomal membrane was abolished in GAT1-deficient mice, and E2730 selectively inhibited GAT1-mediated GABA uptake over other GABA transporters. In addition, results of GABA uptake assays showed that E2730-mediated inhibition of GAT1 positively correlated to the level of ambient GABA in vitro. E2730 also increased extracellular GABA concentration in hyperactivated conditions but not under basal levels in vivo., Significance: E2730 is a novel, selective, uncompetitive GAT1 inhibitor, which acts selectively under the condition of increasing synaptic activity, contributing to a wide margin between therapeutic effect and motor incoordination., (© 2023 The Authors. Epilepsia Open published by Wiley Periodicals LLC on behalf of International League Against Epilepsy.)- Published
- 2023
- Full Text
- View/download PDF
8. Anti-seizure efficacy of perampanel in two established rodent models of early-life epilepsy.
- Author
-
Roberts NS, Handy MJ, Ito Y, Hashimoto K, Jensen FE, and Talos DM
- Subjects
- Mice, Rats, Animals, Anticonvulsants adverse effects, Treatment Outcome, Pyridones, Rodentia, Epilepsy drug therapy
- Abstract
Early-life seizures can be refractory to conventional antiseizure medications (ASMs) and can also result in chronic epilepsy and long-term behavioral and cognitive deficits. Treatments targeting age-specific mechanisms contributing to epilepsy would be of clinical benefit. One such target is the α-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid receptor (AMPAR) subtype of excitatory glutamate receptor, which is upregulated in the developing brain. Perampanel is a non-competitive, selective AMPAR antagonist that is FDA-approved for focal onset seizures (FOS) or primary generalized tonic-clonic seizures (PGTC) in children and adults. However, the efficacy of perampanel treatment in epilepsy patients younger than 4 years has been less documented. We thus tested the efficacy of perampanel in two early-life seizure models: (1) a rat model of hypoxia-induced neonatal seizures and (2) a mouse model of Dravet syndrome with hyperthermia-induced seizures. Pretreatment with perampanel conferred dose-dependent protection against early-life seizures in both experimental models. These findings suggest that AMPAR-mediated hyperexcitability could be involved in the pathophysiology of early-life seizures, which may be amenable to treatment with perampanel., Competing Interests: Declaration of Competing Interest The authors declare the following financial interests/personal relationships which may be considered as potential competing interests: Nicholas S. Roberts, Marcus J. Handy, Delia M. Talos, and Frances E. Jensen are employees of the University of Pennsylvania, Perelman School of Medicine, Pennsylvania, PA, USA. Yoshimasa Ito was an employee of Eisai Co. Ltd. during these works and is now retired. Keisuke Hashimoto is an employee of Eisai Co. Ltd. Delia M. Talos and Frances E. Jensen have served at scientific advisory board meetings for Eisai Co. Ltd on topics unrelated to this work., (Copyright © 2023 Elsevier Inc. All rights reserved.)
- Published
- 2023
- Full Text
- View/download PDF
9. Optical Redox Imaging of Ex Vivo Hippocampal Tissue Reveals Age-Dependent Alterations in the 5XFAD Mouse Model of Alzheimer's Disease.
- Author
-
Xu HN, Gourmaud S, Podsednik A, Li X, Zhao H, Jensen FE, Talos DM, and Li LZ
- Abstract
A substantial decline in nicotinamide adenine dinucleotide (NAD) has been reported in brain tissue homogenates or neurons isolated from Alzheimer's disease (AD) models. NAD, together with flavin adenine dinucleotide (FAD), critically supports energy metabolism and maintains mitochondrial redox homeostasis. Optical redox imaging (ORI) of the intrinsic fluorescence of reduced NAD (NADH) and oxidized FAD yields cellular redox and metabolic information and provides biomarkers for a variety of pathological conditions. However, its utility in AD has not been characterized at the tissue level. We performed ex vivo ORI of freshly dissected hippocampi from a well-characterized AD mouse model with five familial Alzheimer's disease mutations (5XFAD) and wild type (WT) control littermates at various ages. We found (1) a significant increase in the redox ratio with age in the hippocampi of both the WT control and the 5XFAD model, with a more prominent redox shift in the AD hippocampi; (2) a higher NADH in the 5XFAD versus WT hippocampi at the pre-symptomatic age of 2 months; and (3) a negative correlation between NADH and Aβ
42 level, a positive correlation between Fp and Aβ42 level, and a positive correlation between redox ratio and Aβ42 level in the AD hippocampi. These findings suggest that the ORI can be further optimized to conveniently study the metabolism of freshly dissected brain tissues in animal models and identify early AD biomarkers.- Published
- 2022
- Full Text
- View/download PDF
10. The role of mTORC1 activation in seizure-induced exacerbation of Alzheimer's disease.
- Author
-
Gourmaud S, Stewart DA, Irwin DJ, Roberts N, Barbour AJ, Eberwine G, O'Brien WT, Vassar R, Talos DM, and Jensen FE
- Subjects
- Amyloid beta-Peptides metabolism, Animals, Disease Models, Animal, Humans, Mechanistic Target of Rapamycin Complex 1, Mice, Pentylenetetrazole toxicity, Seizures metabolism, Alzheimer Disease pathology
- Abstract
The risk of seizures is 10-fold higher in patients with Alzheimer's disease than the general population, yet the mechanisms underlying this susceptibility and the effects of these seizures are poorly understood. To elucidate the proposed bidirectional relationship between Alzheimer's disease and seizures, we studied human brain samples (n = 34) from patients with Alzheimer's disease and found that those with a history of seizures (n = 14) had increased amyloid-β and tau pathology, with upregulation of the mechanistic target of rapamycin (mTOR) pathway, compared with patients without a known history of seizures (n = 20). To establish whether seizures accelerate the progression of Alzheimer's disease, we induced chronic hyperexcitability in the five times familial Alzheimer's disease mouse model by kindling with the chemoconvulsant pentylenetetrazol and observed that the mouse model exhibited more severe seizures than the wild-type. Furthermore, kindled seizures exacerbated later cognitive impairment, Alzheimer's disease neuropathology and mTOR complex 1 activation. Finally, we demonstrated that the administration of the mTOR inhibitor rapamycin following kindled seizures rescued enhanced remote and long-term memory deficits associated with earlier kindling and prevented seizure-induced increases in Alzheimer's disease neuropathology. These data demonstrated an important link between chronic hyperexcitability and progressive Alzheimer's disease pathology and suggest a mechanism whereby rapamycin may serve as an adjunct therapy to attenuate progression of the disease., (© The Author(s) (2021). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2022
- Full Text
- View/download PDF
11. Alzheimer-like amyloid and tau alterations associated with cognitive deficit in temporal lobe epilepsy.
- Author
-
Gourmaud S, Shou H, Irwin DJ, Sansalone K, Jacobs LM, Lucas TH, Marsh ED, Davis KA, Jensen FE, and Talos DM
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Alzheimer Disease metabolism, Alzheimer Disease pathology, Amyloid beta-Protein Precursor metabolism, Autopsy, Case-Control Studies, Child, Child, Preschool, Cognitive Dysfunction complications, Cognitive Dysfunction metabolism, Cognitive Dysfunction physiopathology, Drug Resistant Epilepsy complications, Drug Resistant Epilepsy metabolism, Drug Resistant Epilepsy pathology, Drug Resistant Epilepsy surgery, Epilepsy, Temporal Lobe complications, Epilepsy, Temporal Lobe metabolism, Epilepsy, Temporal Lobe surgery, Female, Hippocampus metabolism, Hippocampus surgery, Humans, JNK Mitogen-Activated Protein Kinases metabolism, Male, Middle Aged, Neurosurgical Procedures, Plaque, Amyloid metabolism, Temporal Lobe metabolism, Temporal Lobe surgery, Young Adult, eIF-2 Kinase metabolism, Amyloid beta-Peptides metabolism, Cognitive Dysfunction pathology, Epilepsy, Temporal Lobe pathology, Hippocampus pathology, Peptide Fragments metabolism, Plaque, Amyloid pathology, Temporal Lobe pathology, tau Proteins metabolism
- Abstract
Temporal lobe epilepsy represents a major cause of drug-resistant epilepsy. Cognitive impairment is a frequent comorbidity, but the mechanisms are not fully elucidated. We hypothesized that the cognitive impairment in drug-resistant temporal lobe epilepsy could be due to perturbations of amyloid and tau signalling pathways related to activation of stress kinases, similar to those observed in Alzheimer's disease. We examined these pathways, as well as amyloid-β and tau pathologies in the hippocampus and temporal lobe cortex of drug-resistant temporal lobe epilepsy patients who underwent temporal lobe resection (n = 19), in comparison with age- and region-matched samples from neurologically normal autopsy cases (n = 22). Post-mortem temporal cortex samples from Alzheimer's disease patients (n = 9) were used as positive controls to validate many of the neurodegeneration-related antibodies. Western blot and immunohistochemical analysis of tissue from temporal lobe epilepsy cases revealed increased phosphorylation of full-length amyloid precursor protein and its associated neurotoxic cleavage product amyloid-β*56. Pathological phosphorylation of two distinct tau species was also increased in both regions, but increases in amyloid-β1-42 peptide, the main component of amyloid plaques, were restricted to the hippocampus. Furthermore, several major stress kinases involved in the development of Alzheimer's disease pathology were significantly activated in temporal lobe epilepsy brain samples, including the c-Jun N-terminal kinase and the protein kinase R-like endoplasmic reticulum kinase. In temporal lobe epilepsy cases, hippocampal levels of phosphorylated amyloid precursor protein, its pro-amyloidogenic processing enzyme beta-site amyloid precursor protein cleaving enzyme 1, and both total and hyperphosphorylated tau expression, correlated with impaired preoperative executive function. Our study suggests that neurodegenerative and stress-related processes common to those observed in Alzheimer's disease may contribute to cognitive impairment in drug-resistant temporal lobe epilepsy. In particular, we identified several stress pathways that may represent potential novel therapeutic targets., (© The Author(s) (2019). Published by Oxford University Press on behalf of the Guarantors of Brain. All rights reserved. For permissions, please email: journals.permissions@oup.com.)
- Published
- 2020
- Full Text
- View/download PDF
12. Mechanistic target of rapamycin complex 1 and 2 in human temporal lobe epilepsy.
- Author
-
Talos DM, Jacobs LM, Gourmaud S, Coto CA, Sun H, Lim KC, Lucas TH, Davis KA, Martinez-Lage M, and Jensen FE
- Subjects
- Adult, Brain metabolism, Epilepsy, Temporal Lobe physiopathology, Female, Humans, Male, Middle Aged, TOR Serine-Threonine Kinases metabolism, Young Adult, Epilepsy, Temporal Lobe metabolism, Mechanistic Target of Rapamycin Complex 1 metabolism, Mechanistic Target of Rapamycin Complex 2 metabolism, Signal Transduction physiology
- Abstract
Objective: Temporal lobe epilepsy (TLE) is a chronic epilepsy syndrome defined by seizures and progressive neurological disabilities, including cognitive impairments, anxiety, and depression. Here, human TLE specimens were investigated focusing on the mechanistic target of rapamycin (mTOR) complex 1 (mTORC1) and complex 2 (mTORC2) activities in the brain, given that both pathways may represent unique targets for treatment., Methods: Surgically resected hippocampal and temporal lobe samples from therapy-resistant TLE patients were analyzed by western blotting to quantify the expression of established mTORC1 and mTORC2 activity markers and upstream or downstream signaling pathways involving the two complexes. Histological and immunohistochemical techniques were used to assess hippocampal and neocortical structural abnormalities and cell-specific expression of individual biomarkers. Samples from patients with focal cortical dysplasia (FCD) type II served as positive controls., Results: We found significantly increased expression of phospho-mTOR (Ser2448), phospho-S6 (Ser235/236), phospho-S6 (Ser240/244), and phospho-Akt (Ser473) in TLE samples compared to controls, consistent with activation of both mTORC1 and mTORC2. Our work identified the phosphoinositide 3-kinase and Ras/extracellular signal-regulated kinase signaling pathways as potential mTORC1 and mTORC2 upstream activators. In addition, we found that overactive mTORC2 signaling was accompanied by induction of two protein kinase B-dependent prosurvival pathways, as evidenced by increased inhibitory phosphorylation of forkhead box class O3a (Ser253) and glycogen synthase kinase 3 beta (Ser9)., Interpretation: Our data demonstrate that mTOR signaling is significantly dysregulated in human TLE, offering new targets for pharmacological interventions. Specifically, clinically available drugs that suppress mTORC1 without compromising mTOR2 signaling, such as rapamycin and its analogs, may represent a new group of antiepileptogenic agents in TLE patients. Ann Neurol 2018;83:311-327., (© 2018 American Neurological Association.)
- Published
- 2018
- Full Text
- View/download PDF
13. Developmental expression of N-methyl-D-aspartate (NMDA) receptor subunits in human white and gray matter: potential mechanism of increased vulnerability in the immature brain.
- Author
-
Jantzie LL, Talos DM, Jackson MC, Park HK, Graham DA, Lechpammer M, Folkerth RD, Volpe JJ, and Jensen FE
- Subjects
- Adult, Brain embryology, Brain metabolism, Child, Child, Preschool, Female, Gray Matter embryology, Gray Matter metabolism, Humans, Infant, Infant, Newborn, Leukomalacia, Periventricular metabolism, Male, Middle Aged, White Matter embryology, White Matter metabolism, Brain growth & development, Gray Matter growth & development, Receptors, N-Methyl-D-Aspartate metabolism, White Matter growth & development
- Abstract
The pathophysiology of perinatal brain injury is multifactorial and involves hypoxia-ischemia (HI) and inflammation. N-methyl-d-aspartate receptors (NMDAR) are present on neurons and glia in immature rodents, and NMDAR antagonists are protective in HI models. To enhance clinical translation of rodent data, we examined protein expression of 6 NMDAR subunits in postmortem human brains without injury from 20 postconceptional weeks through adulthood and in cases of periventricular leukomalacia (PVL). We hypothesized that the developing brain is intrinsically vulnerable to excitotoxicity via maturation-specific NMDAR levels and subunit composition. In normal white matter, NR1 and NR2B levels were highest in the preterm period compared with adult. In gray matter, NR2A and NR3A expression were highest near term. NR2A was significantly elevated in PVL white matter, with reduced NR1 and NR3A in gray matter compared with uninjured controls. These data suggest increased NMDAR-mediated vulnerability during early brain development due to an overall upregulation of individual receptors subunits, in particular, the presence of highly calcium permeable NR2B-containing and magnesium-insensitive NR3A NMDARs. These data improve understanding of molecular diversity and heterogeneity of NMDAR subunit expression in human brain development and supports an intrinsic prenatal vulnerability to glutamate-mediated injury; validating NMDAR subunit-specific targeted therapies for PVL., (© The Author 2013. Published by Oxford University Press. All rights reserved. For Permissions, please e-mail: journals.permissions@oup.com.)
- Published
- 2015
- Full Text
- View/download PDF
14. Neuronal Tsc1/2 complex controls autophagy through AMPK-dependent regulation of ULK1.
- Author
-
Di Nardo A, Wertz MH, Kwiatkowski E, Tsai PT, Leech JD, Greene-Colozzi E, Goto J, Dilsiz P, Talos DM, Clish CB, Kwiatkowski DJ, and Sahin M
- Subjects
- Animals, Autophagy-Related Protein-1 Homolog, Cells, Cultured, Disease Models, Animal, Gene Knockdown Techniques, HEK293 Cells, Hippocampus cytology, Humans, Mechanistic Target of Rapamycin Complex 1, Mice, Multiprotein Complexes metabolism, Rats, Signal Transduction, TOR Serine-Threonine Kinases metabolism, Tuberous Sclerosis Complex 1 Protein, Tuberous Sclerosis Complex 2 Protein, Tumor Suppressor Proteins genetics, AMP-Activated Protein Kinases metabolism, Autophagy, Intracellular Signaling Peptides and Proteins metabolism, Neurons metabolism, Protein Serine-Threonine Kinases metabolism, Tuberous Sclerosis metabolism, Tumor Suppressor Proteins metabolism
- Abstract
Tuberous sclerosis complex (TSC) is a disorder arising from mutation in the TSC1 or TSC2 gene, characterized by the development of hamartomas in various organs and neurological manifestations including epilepsy, intellectual disability and autism. TSC1/2 protein complex negatively regulates the mammalian target of rapamycin complex 1 (mTORC1) a master regulator of protein synthesis, cell growth and autophagy. Autophagy is a cellular quality-control process that sequesters cytosolic material in double membrane vesicles called autophagosomes and degrades it in autolysosomes. Previous studies in dividing cells have shown that mTORC1 blocks autophagy through inhibition of Unc-51-like-kinase1/2 (ULK1/2). Despite the fact that autophagy plays critical roles in neuronal homeostasis, little is known on the regulation of autophagy in neurons. Here we show that unlike in non-neuronal cells, Tsc2-deficient neurons have increased autolysosome accumulation and autophagic flux despite mTORC1-dependent inhibition of ULK1. Our data demonstrate that loss of Tsc2 results in autophagic activity via AMPK-dependent activation of ULK1. Thus, in Tsc2-knockdown neurons AMPK activation is the dominant regulator of autophagy. Notably, increased AMPK activity and autophagy activation are also found in the brains of Tsc1-conditional mouse models and in cortical tubers resected from TSC patients. Together, our findings indicate that neuronal Tsc1/2 complex activity is required for the coordinated regulation of autophagy by AMPK. By uncovering the autophagy dysfunction associated with Tsc2 loss in neurons, our work sheds light on a previously uncharacterized cellular mechanism that contributes to altered neuronal homeostasis in TSC disease., (© The Author 2014. Published by Oxford University Press. All rights reserved. For Permissions, please email: journals.permissions@oup.com.)
- Published
- 2014
- Full Text
- View/download PDF
15. Subunit composition of glutamate and gamma-aminobutyric acid receptors in status epilepticus.
- Author
-
Loddenkemper T, Talos DM, Cleary RT, Joseph A, Sánchez Fernández I, Alexopoulos A, Kotagal P, Najm I, and Jensen FE
- Subjects
- Adolescent, Child, Child, Preschool, Female, Humans, Infant, Infant, Newborn, Male, Young Adult, Cerebral Cortex metabolism, Protein Subunits metabolism, Receptors, GABA metabolism, Receptors, Glutamate metabolism, Status Epilepticus metabolism
- Abstract
Purpose: To describe the subunit composition of glutamate and gamma-aminobutyric acid (GABA) receptors in brain tissue from patients with different types of status epilepticus., Patients and Methods: The subunit composition of glutamate and GABA receptors was analyzed in: (1) surgical brain samples from three patients with refractory convulsive status epilepticus, three patients with electrical status epilepticus in sleep, and six patients with refractory epilepsy, and (2) brain autopsy samples from four controls who died without neurological disorders. Subunit expression was quantified with Western blotting and messenger ribonucleic acid (mRNA) expression was quantified with reverse polymerase chain reaction., Results: Western blot analysis demonstrated the following patterns (as compared to controls): (1) alpha-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA) receptors: elevated GluA1/GluA2 ratio in electrical status epilepticus in sleep (465%±119) and refractory epilepsy (329%±125; p<0.01); (2) N-methyl-d-aspartate (NMDA) receptors: increased GluN2B/GluN2A ratio in electrical status epilepticus in sleep (3682%±1000) and refractory convulsive status epilepticus (3520%±751; p<0.05); (3) GABA receptors: elevated α2/α1 ratio in refractory epilepsy (321%±138; p<0.05) and refractory convulsive status epilepticus (346%±74; p<0.05); and (4) patients with underlying malformation of cortical development had increased ratios in GluA1/GluA2 (382%±149; p<0.01), GluN2B/GluN2A (3321%±1581; p<0.05) and α2/α1 (303%±86; p<0.01). Quantification of mRNA demonstrated an elevated GABRA2/GABRA1 ratio in refractory epilepsy (712; p<0.05) as compared to controls., Conclusions: The subunit composition of glutamate and GABA receptors in patients with status epilepticus mirrors that found in animal models of refractory status epilepticus and may promote self-sustaining seizures. Receptor subunit changes may provide additional targets for improved treatment., (Copyright © 2014 Elsevier B.V. All rights reserved.)
- Published
- 2014
- Full Text
- View/download PDF
16. Developmental brain abnormalities in tuberous sclerosis complex: a comparative tissue analysis of cortical tubers and perituberal cortex.
- Author
-
Ruppe V, Dilsiz P, Reiss CS, Carlson C, Devinsky O, Zagzag D, Weiner HL, and Talos DM
- Subjects
- Brain growth & development, Brain Diseases metabolism, Brain Diseases pathology, Cerebral Cortex abnormalities, Cerebral Cortex growth & development, Cerebral Cortex pathology, Female, Humans, Male, Prospective Studies, Tuberous Sclerosis metabolism, Tuberous Sclerosis pathology, Brain abnormalities, Brain Diseases diagnosis, Tuberous Sclerosis diagnosis
- Abstract
Objective: Genetic loss of Tsc1/Tsc2 function in tuberous sclerosis complex (TSC) results in altered mammalian target of rapamycin (mTOR) signaling and abnormal brain development. Although earlier studies have focused on characterization of cortical tubers, in this study we sought to examine the unique cellular and molecular features of the perituberal cortex in order to better understand its contribution to epileptogenesis, cognitive dysfunction, and autism., Methods: Standard histologic and immunohistochemical labeling was used to assess structural abnormalities and cell-specific pattern of mTORC1 activation in surgically resected cortical tubers and perituberal cortex. Western blotting was performed to quantify the expression of the mTORC1 and mTORC2 biomarkers phospho-S6 (Ser235/236), phospho-S6 (Ser240/244), and phospho-Akt (Ser473), in addition to evaluating the differential expression levels of several neuronal and glial-specific proteins in tubers and peritubers, as compared to non-TSC epilepsy specimens., Results: Tubers demonstrated mild to severe disruption of cortical lamination, the presence of pS6-positive dysplastic neurons and giant cells, an overall increase in mTORC1 and a decrease in mTORC2 activity, increased axonal connectivity and growth, and hypomyelination. Perituberal cortex presented similar histologic, immunohistochemical, and molecular features; however, they were overall milder. Axonal growth was specific for TSC and was negatively correlated with deficient myelination., Significance: Our results show an extension of cellular dysplasia and dysregulated mTOR signaling in the perituberal tissue, and demonstrate for the first time aberrant connectivity in human TSC brain. This study provides new insights into the pathophysiology of neurologic dysfunction associated with TSC and supports the intrinsic epileptogenicity of normal-appearing perituberal cortex. A PowerPoint slide summarizing this article is available for download in the Supporting Information section here., (Wiley Periodicals, Inc. © 2014 International League Against Epilepsy.)
- Published
- 2014
- Full Text
- View/download PDF
17. Antiepileptic effects of levetiracetam in a rodent neonatal seizure model.
- Author
-
Talos DM, Chang M, Kosaras B, Fitzgerald E, Murphy A, Folkerth RD, and Jensen FE
- Subjects
- Animals, Animals, Newborn, Blotting, Western, Brain metabolism, Immunohistochemistry, Kainic Acid toxicity, Levetiracetam, Membrane Glycoproteins metabolism, Nerve Tissue Proteins metabolism, Piracetam metabolism, Piracetam therapeutic use, Rats, Seizures chemically induced, Anticonvulsants therapeutic use, Piracetam analogs & derivatives, Seizures drug therapy, Seizures prevention & control
- Abstract
Background: Neonatal seizures can result in chronic epilepsy and long-term behavioral and cognitive deficits. Levetiracetam (LEV), an antiepileptic drug that binds to the synaptic vesicle protein 2A (SV2A), has been increasingly used off-label for the therapy of neonatal seizures. Preclinical data regarding the acute or long-term efficacy of LEV are lacking., Methods: We tested the anticonvulsant efficacy of LEV in a rat model of hypoxia-induced neonatal seizures. In addition, we evaluated the protective effects of postnatal day (P)10 LEV treatment on later-life kainic acid (KA)-induced seizure susceptibility and seizure-induced neuronal injury. Western blot and immunohistochemistry were used to assess the developmental regulation of SV2A in the rat and human brain., Results: LEV pretreatment at P10 significantly decreased the cumulative duration of behavioral and electrographic seizures at both 25 and 50 mg/kg. At P40, KA-induced seizures and neuronal loss were significantly diminished in rats previously treated with LEV. LEV target SV2A is present in both neonatal rat and human brain and increases steadily to adulthood., Conclusion: LEV suppressed acute seizures induced by perinatal hypoxia and diminished later-life seizure susceptibility and seizure-induced neuronal injury, providing evidence for disease modification. These results support consideration of a clinical trial of LEV in neonatal seizures.
- Published
- 2013
- Full Text
- View/download PDF
18. Bumetanide enhances phenobarbital efficacy in a rat model of hypoxic neonatal seizures.
- Author
-
Cleary RT, Sun H, Huynh T, Manning SM, Li Y, Rotenberg A, Talos DM, Kahle KT, Jackson M, Rakhade SN, Berry G, and Jensen FE
- Subjects
- Animals, Animals, Newborn, Anticonvulsants administration & dosage, Anticonvulsants pharmacology, Behavior, Animal drug effects, Brain drug effects, Brain metabolism, Bumetanide pharmacokinetics, CA1 Region, Hippocampal drug effects, CA1 Region, Hippocampal metabolism, Cell Death drug effects, Drug Synergism, Drug Therapy, Combination, Electroencephalography, Evoked Potentials drug effects, Male, Neurons drug effects, Neurons metabolism, Phenobarbital pharmacokinetics, Rats, Seizures drug therapy, Seizures metabolism, Seizures physiopathology, Sodium Potassium Chloride Symporter Inhibitors administration & dosage, Sodium Potassium Chloride Symporter Inhibitors pharmacology, Solute Carrier Family 12, Member 2 metabolism, Symporters metabolism, K Cl- Cotransporters, Bumetanide administration & dosage, Hypoxia complications, Phenobarbital administration & dosage, Seizures etiology
- Abstract
Neonatal seizures can be refractory to conventional anticonvulsants, and this may in part be due to a developmental increase in expression of the neuronal Na(+)-K(+)-2 Cl(-) cotransporter, NKCC1, and consequent paradoxical excitatory actions of GABAA receptors in the perinatal period. The most common cause of neonatal seizures is hypoxic encephalopathy, and here we show in an established model of neonatal hypoxia-induced seizures that the NKCC1 inhibitor, bumetanide, in combination with phenobarbital is significantly more effective than phenobarbital alone. A sensitive mass spectrometry assay revealed that bumetanide concentrations in serum and brain were dose-dependent, and the expression of NKCC1 protein transiently increased in cortex and hippocampus after hypoxic seizures. Importantly, the low doses of phenobarbital and bumetanide used in the study did not increase constitutive apoptosis, alone or in combination. Perforated patch clamp recordings from ex vivo hippocampal slices removed following seizures revealed that phenobarbital and bumetanide largely reversed seizure-induced changes in EGABA. Taken together, these data provide preclinical support for clinical trials of bumetanide in human neonates at risk for hypoxic encephalopathy and seizures.
- Published
- 2013
- Full Text
- View/download PDF
19. Altered inhibition in tuberous sclerosis and type IIb cortical dysplasia.
- Author
-
Talos DM, Sun H, Kosaras B, Joseph A, Folkerth RD, Poduri A, Madsen JR, Black PM, and Jensen FE
- Subjects
- Adolescent, Adult, Blotting, Western, Brain metabolism, Brain pathology, Brain Diseases complications, Brain Diseases pathology, Child, Child, Preschool, Epilepsy etiology, Epilepsy metabolism, Epilepsy pathology, Female, Humans, Immunohistochemistry, Infant, Male, Malformations of Cortical Development complications, Malformations of Cortical Development pathology, Malformations of Cortical Development, Group I, Neurons pathology, Patch-Clamp Techniques, Receptors, GABA biosynthesis, Sodium-Potassium-Chloride Symporters biosynthesis, Solute Carrier Family 12, Member 2, Symporters biosynthesis, Tuberous Sclerosis complications, Tuberous Sclerosis pathology, Young Adult, K Cl- Cotransporters, Brain Diseases metabolism, Malformations of Cortical Development metabolism, Neural Inhibition physiology, Neurons metabolism, Tuberous Sclerosis metabolism
- Abstract
Objective: The most common neurological symptom of tuberous sclerosis complex (TSC) and focal cortical dysplasia (FCD) is early life refractory epilepsy. As previous studies have shown enhanced excitatory glutamatergic neurotransmission in TSC and FCD brains, we hypothesized that neurons associated with these lesions may also express altered γ-aminobutyric acid (GABA)(A) receptor (GABA(A)R)-mediated inhibition., Methods: Expression of the GABA(A)R subunits α1 and α4, and the Na(+)-K(+)-2Cl(-) (NKCC1) and the K(+)-Cl(-) (KCC2) transporters, in human TSC and FCD type II specimens were analyzed by Western blot and double label immunocytochemistry. GABA(A) R responses in dysplastic neurons from a single case of TSC were measured by perforated patch recording and compared to normal-appearing cortical neurons from a non-TSC epilepsy case., Results: TSC and FCD type IIb lesions demonstrated decreased expression of GABA(A)R α1, and increased NKCC1 and decreased KCC2 levels. In contrast, FCD type IIa lesions showed decreased α4, and increased expression of both NKCC1 and KCC2 transporters. Patch clamp recordings from dysplastic neurons in acute slices from TSC tubers demonstrated excitatory GABA(A)R responses that were significantly attenuated by the NKCC1 inhibitor bumetanide, in contrast to hyperpolarizing GABA(A)R-mediated currents in normal neurons from non-TSC cortical slices., Interpretation: Expression and function of GABA(A)Rs in TSC and FCD type IIb suggest the relative benzodiazepine insensitivity and more excitatory action of GABA compared to FCD type IIa. These factors may contribute to resistance of seizure activity to anticonvulsants that increase GABAergic function, and may justify add-on trials of the NKCC1 inhibitor bumetanide for the treatment of TSC and FCD type IIb-related epilepsy., (Copyright © 2012 American Neurological Association.)
- Published
- 2012
- Full Text
- View/download PDF
20. The interaction between early life epilepsy and autistic-like behavioral consequences: a role for the mammalian target of rapamycin (mTOR) pathway.
- Author
-
Talos DM, Sun H, Zhou X, Fitzgerald EC, Jackson MC, Klein PM, Lan VJ, Joseph A, and Jensen FE
- Subjects
- Animals, Behavior, Animal physiology, Blotting, Western, Epilepsy physiopathology, Immunohistochemistry, Kainic Acid pharmacology, Locomotion physiology, Male, Rats, Seizures chemically induced, Seizures metabolism, Epilepsy metabolism, TOR Serine-Threonine Kinases metabolism
- Abstract
Early life seizures can result in chronic epilepsy, cognitive deficits and behavioral changes such as autism, and conversely epilepsy is common in autistic children. We hypothesized that during early brain development, seizures could alter regulators of synaptic development and underlie the interaction between epilepsy and autism. The mammalian Target of Rapamycin (mTOR) modulates protein translation and is dysregulated in Tuberous Sclerosis Complex, a disorder characterized by epilepsy and autism. We used a rodent model of acute hypoxia-induced neonatal seizures that results in long term increases in neuronal excitability, seizure susceptibility, and spontaneous seizures, to determine how seizures alter mTOR Complex 1 (mTORC1) signaling. We hypothesized that seizures occurring at a developmental stage coinciding with a critical period of synaptogenesis will activate mTORC1, contributing to epileptic networks and autistic-like behavior in later life. Here we show that in the rat, baseline mTORC1 activation peaks during the first three postnatal weeks, and induction of seizures at postnatal day 10 results in further transient activation of its downstream targets phospho-4E-BP1 (Thr37/46), phospho-p70S6K (Thr389) and phospho-S6 (Ser235/236), as well as rapid induction of activity-dependent upstream signaling molecules, including BDNF, phospho-Akt (Thr308) and phospho-ERK (Thr202/Tyr204). Furthermore, treatment with the mTORC1 inhibitor rapamycin immediately before and after seizures reversed early increases in glutamatergic neurotransmission and seizure susceptibility and attenuated later life epilepsy and autistic-like behavior. Together, these findings suggest that in the developing brain the mTORC1 signaling pathway is involved in epileptogenesis and altered social behavior, and that it may be a target for development of novel therapies that eliminate the progressive effects of neonatal seizures.
- Published
- 2012
- Full Text
- View/download PDF
21. Regulable neural progenitor-specific Tsc1 loss yields giant cells with organellar dysfunction in a model of tuberous sclerosis complex.
- Author
-
Goto J, Talos DM, Klein P, Qin W, Chekaluk YI, Anderl S, Malinowska IA, Di Nardo A, Bronson RT, Chan JA, Vinters HV, Kernie SG, Jensen FE, Sahin M, and Kwiatkowski DJ
- Subjects
- Animals, Blotting, Western, Cell Survival drug effects, Humans, Mice, Microscopy, Electron, Microscopy, Fluorescence, Polymerase Chain Reaction, Sirolimus pharmacology, Tuberous Sclerosis genetics, Tuberous Sclerosis Complex 1 Protein, Tumor Suppressor Proteins genetics, Tumor Suppressor Proteins metabolism, Disease Models, Animal, Neurons metabolism, Stem Cells metabolism, Tuberous Sclerosis pathology, Tumor Suppressor Proteins physiology
- Abstract
Tuberous sclerosis complex (TSC) is a multiorgan genetic disease in which brain involvement causes epilepsy, intellectual disability, and autism. The hallmark pathological finding in TSC is the cerebral cortical tuber and its unique constituent, giant cells. However, an animal model that replicates giant cells has not yet been described. Here, we report that mosaic induction of Tsc1 loss in neural progenitor cells in Tsc1(cc) Nestin-rtTA(+) TetOp-cre(+) embryos by doxycycline leads to multiple neurological symptoms, including severe epilepsy and premature death. Strikingly, Tsc1-null neural progenitor cells develop into highly enlarged giant cells with enlarged vacuoles. We found that the vacuolated giant cells had multiple signs of organelle dysfunction, including markedly increased mitochondria, aberrant lysosomes, and elevated cellular stress. We found similar vacuolated giant cells in human tuber specimens. Postnatal rapamycin treatment completely reversed these phenotypes and rescued the mutants from epilepsy and premature death, despite prenatal onset of Tsc1 loss and mTOR complex 1 activation in the developing brain. This TSC brain model provides insights into the pathogenesis and organelle dysfunction of giant cells, as well as epilepsy control in patients with TSC.
- Published
- 2011
- Full Text
- View/download PDF
22. Developmental regulation of group I metabotropic glutamate receptors in the premature brain and their protective role in a rodent model of periventricular leukomalacia.
- Author
-
Jantzie LL, Talos DM, Selip DB, An L, Jackson MC, Folkerth RD, Deng W, and Jensen FE
- Subjects
- Age Factors, Animals, Animals, Newborn, Dioxolanes administration & dosage, Disease Models, Animal, Fetus, Galactosylceramidase metabolism, Humans, Hypoxia-Ischemia, Brain complications, Infant, Newborn, Leukomalacia, Periventricular etiology, Oligodendroglia metabolism, Purines administration & dosage, Rats, Rats, Long-Evans, Receptor, Metabotropic Glutamate 5, Brain growth & development, Brain metabolism, Gene Expression Regulation, Developmental physiology, Leukomalacia, Periventricular metabolism, Leukomalacia, Periventricular prevention & control, Receptors, Metabotropic Glutamate metabolism
- Abstract
Cerebral white matter injury in premature infants, known as periventricular leukomalacia (PVL), is common after hypoxia-ischemia (HI). While ionotropic glutamate receptors (iGluRs) can mediate immature white matter injury, we have previously shown that excitotoxic injury to premyelinating oligodendrocytes (preOLs) in vitro can be attenuated by group I metabotropic glutamate receptor (mGluR) agonists. Thus, we evaluated mGluR expression in developing white matter in rat and human brain, and tested the protective efficacy of a central nervous system (CNS)-penetrating mGluR agonist on injury to developing oligodendrocytes (OLs) in vivo. Group I mGluRs (mGluR1 and mGluR5) were strongly expressed on OLs in neonatal rodent cerebral white matter throughout normal development, with highest expression early in development on preOLs. Specifically at P6, mGluR1 and mGLuR5 were most highly expressed on GalC-positive OLs compared to neurons, axons, astrocytes and microglia. Systemic administration of (1S,3R) 1-aminocyclopentane-trans-1,3,-dicarboxylic acid (ACPD) significantly attenuated the loss of myelin basic protein in the white matter following HI in P6 rats. Assessment of postmortem human tissue showed both mGluR1 and mGluR5 localized on immature OLs in white matter throughout development, with mGluR5 highest in the preterm period. These data indicate group I mGluRs are highly expressed on OLs during the peak period of vulnerability to HI and modulation of mGluRs is protective in a rodent model of PVL. Group I mGluRs may represent important therapeutic targets for protection from HI-mediated white matter injury.
- Published
- 2010
- Full Text
- View/download PDF
23. Minocycline treatment following hypoxic/ischaemic injury attenuates white matter injury in a rodent model of periventricular leucomalacia.
- Author
-
Lechpammer M, Manning SM, Samonte F, Nelligan J, Sabo E, Talos DM, Volpe JJ, and Jensen FE
- Subjects
- Animals, Animals, Newborn, Cell Death, Disease Models, Animal, Humans, Hypoxia, Brain pathology, Hypoxia-Ischemia, Brain etiology, Hypoxia-Ischemia, Brain pathology, Infant, Newborn, Leukomalacia, Periventricular pathology, Microglia drug effects, Myelin Basic Protein metabolism, Rats, Rats, Long-Evans, Tegmentum Mesencephali pathology, Hypoxia-Ischemia, Brain prevention & control, Leukomalacia, Periventricular complications, Leukomalacia, Periventricular physiopathology, Microglia pathology, Minocycline therapeutic use, Tegmentum Mesencephali injuries
- Abstract
Aims: Periventricular white matter injury in premature infants occurs following hypoxia/ischaemia and systemic infection, and results in hypomyelination, as well as neuromotor and cognitive deficits later in life. Inflammatory infiltrates are seen within human cerebral white matter from periventricular leucomalacia (PVL) cases., Methods: In this study, we examine the time course of CD-68+ microglial cell responses relative to cell death within white matter following hypoxia/ischaemia in a rat model of PVL. We also tested the efficacy of the minocycline, an agent that suppresses microglial activation, in this model when administered as a post-insult treatment., Results: We show that preoligodendrocyte injury in the post-natal day 6 begins within 24 h and continues for 48-96 h after hypoxia/ischaemia, and that microglial responses occur primarily over the first 96 h following hypoxia/ischaemia. Minocycline treatment over this 96 h time window following the insult resulted in significant protection against white matter injury, and this effect was concomitant with a reduction in CD-68+ microglial cell numbers., Conclusions: These results suggest that anti-inflammatory treatments may represent a useful strategy in the treatment of PVL, where clinical conditions would favour a post-insult treatment strategy.
- Published
- 2008
- Full Text
- View/download PDF
24. NMDA receptor blockade with memantine attenuates white matter injury in a rat model of periventricular leukomalacia.
- Author
-
Manning SM, Talos DM, Zhou C, Selip DB, Park HK, Park CJ, Volpe JJ, and Jensen FE
- Subjects
- Animals, Animals, Newborn, Antigens, Differentiation metabolism, Biomarkers metabolism, Brain growth & development, Brain physiopathology, Disease Models, Animal, Excitatory Amino Acid Antagonists pharmacology, Excitatory Amino Acid Antagonists therapeutic use, Humans, Hypoxia-Ischemia, Brain drug therapy, Hypoxia-Ischemia, Brain metabolism, Hypoxia-Ischemia, Brain physiopathology, Infant, Newborn, Leukomalacia, Periventricular metabolism, Leukomalacia, Periventricular physiopathology, Male, Memantine therapeutic use, Myelin Basic Protein metabolism, Nerve Fibers, Myelinated metabolism, Nerve Fibers, Myelinated pathology, Oligodendroglia drug effects, Oligodendroglia metabolism, Rats, Rats, Long-Evans, Receptors, N-Methyl-D-Aspartate metabolism, Wallerian Degeneration physiopathology, Wallerian Degeneration prevention & control, Brain drug effects, Leukomalacia, Periventricular drug therapy, Memantine pharmacology, Nerve Fibers, Myelinated drug effects, Receptors, N-Methyl-D-Aspartate antagonists & inhibitors, Wallerian Degeneration drug therapy
- Abstract
Hypoxia-ischemia (H/I) in the premature infant leads to white matter injury termed periventricular leukomalacia (PVL), the leading cause of subsequent neurological deficits. Glutamatergic excitotoxicity in white matter oligodendrocytes (OLs) mediated by cell surface glutamate receptors (GluRs) of the AMPA subtype has been demonstrated as one factor in this injury. Recently, it has been shown that rodent OLs also express functional NMDA GluRs (NMDARs), and overactivation of these receptors can mediate excitotoxic OL injury. Here we show that preterm human developing OLs express NMDARs during the PVL period of susceptibility, presenting a potential therapeutic target. The expression pattern mirrors that seen in the immature rat. Furthermore, the uncompetitive NMDAR antagonist memantine attenuates NMDA-evoked currents in developing OLs in situ in cerebral white matter of immature rats. Using an H/I rat model of white matter injury, we show in vivo that post-H/I treatment with memantine attenuates acute loss of the developing OL cell surface marker O1 and the mature OL marker MBP (myelin basic protein), and also prevents the long-term reduction in cerebral mantle thickness seen at postnatal day 21 in this model. These protective doses of memantine do not affect normal myelination or cortical growth. Together, these data suggest that NMDAR blockade with memantine may provide an effective pharmacological prevention of PVL in the premature infant.
- Published
- 2008
- Full Text
- View/download PDF
25. Cell-specific alterations of glutamate receptor expression in tuberous sclerosis complex cortical tubers.
- Author
-
Talos DM, Kwiatkowski DJ, Cordero K, Black PM, and Jensen FE
- Subjects
- Adolescent, Adult, Cerebral Cortex cytology, Child, Child, Preschool, Excitatory Amino Acid Antagonists therapeutic use, Female, Humans, Infant, Male, Middle Aged, Protein Subunits antagonists & inhibitors, Protein Subunits biosynthesis, Protein Subunits genetics, Receptors, Glutamate genetics, Tuberous Sclerosis genetics, Tuberous Sclerosis Complex 1 Protein, Tuberous Sclerosis Complex 2 Protein, Tumor Suppressor Proteins biosynthesis, Tumor Suppressor Proteins genetics, Cerebral Cortex metabolism, Cerebral Cortex pathology, Gene Expression Regulation physiology, Receptors, Glutamate biosynthesis, Tuberous Sclerosis metabolism, Tuberous Sclerosis pathology
- Abstract
Objective: Genetic loss of TSC1/TSC2 function in tuberous sclerosis complex (TSC) results in overactivation of the mammalian target of rapamycin complex 1 pathway, leading to cellular dysplasia. We hypothesized that the dysplastic cells in TSC tubers are heterogeneous, including separable classes on a neuronal-glial spectrum, and that these dysplastic cells express glutamate receptor (GluR) patterns consistent with increased cortical network excitability., Methods: Surgically resected human cortical tubers and nondysplastic epileptic cortical samples were analyzed by double-label immunocytochemistry for coexpression of neuronal and glial markers, the TSC1/TSC2 pathway downstream molecule phospho-S6 (pS6) and GluR subunits, and compared with control cortical tissue. Western blotting was used to quantify changes in GluR subunit expression in tubers versus controls., Results: We demonstrate that cortical tubers contain a broad spectrum of cell types including disoriented pyramidal cells, dysplastic neurons, giant neuroglial cells, dysplastic astroglia, and reactive astrocytes. Dysplastic neurons, giant cells, and dysplastic astroglia express high levels of pS6 and demonstrate altered GluR subunit composition, resembling those of normal immature neurons and glia. In contrast, nondysplastic neurons in TSC and non-TSC epileptic lesions express lower pS6 levels and display changes in GluR subunit expression that are distinct from the patterns seen in tuber dysplastic cells., Interpretation: This work significantly expands the spectrum of abnormal cells recognized in tubers beyond the classic tuber giant cell and demonstrates cell-specific abnormalities in GluR expression that may contribute to seizure pathogenesis in TSC. Furthermore, these results suggest that subunit-specific antagonists may be of potential use in the treatment of epilepsy in TSC.
- Published
- 2008
- Full Text
- View/download PDF
26. A mouse model of tuberous sclerosis: neuronal loss of Tsc1 causes dysplastic and ectopic neurons, reduced myelination, seizure activity, and limited survival.
- Author
-
Meikle L, Talos DM, Onda H, Pollizzi K, Rotenberg A, Sahin M, Jensen FE, and Kwiatkowski DJ
- Subjects
- Animals, Demyelinating Diseases genetics, Demyelinating Diseases metabolism, Female, Male, Mice, Mice, Inbred C57BL, Mice, Inbred CBA, Mice, Transgenic, Neurons metabolism, Seizures genetics, Seizures metabolism, Survival Rate, Tuberous Sclerosis genetics, Tuberous Sclerosis metabolism, Tuberous Sclerosis mortality, Tuberous Sclerosis Complex 1 Protein, Tumor Suppressor Proteins genetics, Tumor Suppressor Proteins physiology, Demyelinating Diseases pathology, Disease Models, Animal, Neurons pathology, Seizures pathology, Tuberous Sclerosis pathology, Tumor Suppressor Proteins deficiency
- Abstract
Tuberous sclerosis (TSC) is a hamartoma syndrome caused by mutations in TSC1 or TSC2 in which cerebral cortical tubers and seizures are major clinical issues. We have engineered mice in which most cortical neurons lose Tsc1 expression during embryonic development. These Tsc1 mutant mice display several neurological abnormalities beginning at postnatal day 5 with subsequent failure to thrive and median survival of 35 d. The mice also display clinical and electrographic seizures both spontaneously and with physical stimulation, and some seizures end in a fatal tonic phase. Many cortical and hippocampal neurons are enlarged and/or dysplastic in the Tsc1 mutant mice, strongly express phospho-S6, and are ectopic in multiple sites in the cortex and hippocampus. There is a striking delay in myelination in the mutant mice, which appears to be caused by an inductive neuronal defect. This new TSC brain model replicates several features of human TSC brain lesions and implicates an important function of Tsc1/Tsc2 in neuronal development.
- Published
- 2007
- Full Text
- View/download PDF
27. Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. II. Human cerebral white matter and cortex.
- Author
-
Talos DM, Follett PL, Folkerth RD, Fishman RE, Trachtenberg FL, Volpe JJ, and Jensen FE
- Subjects
- Adult, Age Factors, Blotting, Western methods, Cell Count methods, Cerebral Cortex embryology, Cerebral Cortex growth & development, Child, Preschool, Female, Fetus, Gene Expression Regulation, Developmental physiology, Humans, Immunohistochemistry methods, Infant, Infant, Newborn, Male, Membrane Proteins metabolism, Middle Aged, Nerve Tissue Proteins metabolism, Prosencephalon embryology, Prosencephalon growth & development, Cerebral Cortex metabolism, Hypoxia-Ischemia, Brain metabolism, Hypoxia-Ischemia, Brain pathology, Prosencephalon metabolism, Receptors, AMPA metabolism
- Abstract
This report is the second of a two-part evaluation of developmental differences in alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) subunit expression in cell populations within white matter and cortex. In part I, we reported that, in rat, developmental expression of Ca2+-permeable (GluR2-lacking) AMPARs correlated at the regional and cellular level with increased susceptibility to hypoxia/ischemia (H/I), suggesting an age-specific role of these receptors in the pathogenesis of brain injury. Part II examines the regional and cellular progression of AMPAR subunits in human white matter and cortex from midgestation through early childhood. Similarly to the case in the rodent, there is a direct correlation between selective vulnerability to H/I and expression of GluR2-lacking AMPARs in human brain. For midgestational cases aged 20-24 postconceptional weeks (PCW) and for premature infants (25-37 PCW), we found that radial glia, premyelinating oligodendrocytes, and subplate neurons transiently expressed GluR2-lacking AMPARs. Notably, prematurity represents a developmental window of selective vulnerability for white matter injury, such as periventricular leukomalacia (PVL). During term (38-42 PCW) and postterm neonatal (43-46 PCW) periods, age windows characterized by increased susceptibility to cortical injury and seizures, GluR2 expression was low in the neocortex, specifically on cortical pyramidal and nonpyramidal neurons. This study indicates that Ca2+-permeable AMPAR blockade may represent an age-specific therapeutic strategy for potential use in humans. Furthermore, these data help to validate specific rodent maturational stages as appropriate models for evaluation of H/I pathophysiology., (Copyright 2006 Wiley-Liss, Inc.)
- Published
- 2006
- Full Text
- View/download PDF
28. Developmental regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor subunit expression in forebrain and relationship to regional susceptibility to hypoxic/ischemic injury. I. Rodent cerebral white matter and cortex.
- Author
-
Talos DM, Fishman RE, Park H, Folkerth RD, Follett PL, Volpe JJ, and Jensen FE
- Subjects
- Age Factors, Animals, Animals, Newborn, Blotting, Western methods, Cell Count methods, Immunohistochemistry methods, Membrane Proteins metabolism, Nerve Tissue Proteins metabolism, Phosphopyruvate Hydratase metabolism, Protein Subunits metabolism, Rats, Rats, Long-Evans, Receptors, AMPA genetics, gamma-Aminobutyric Acid metabolism, Cerebral Cortex pathology, Gene Expression Regulation, Developmental physiology, Hypoxia-Ischemia, Brain pathology, Prosencephalon growth & development, Prosencephalon metabolism, Receptors, AMPA metabolism
- Abstract
This is the first part of a two-part study to investigate the cellular distribution and temporal regulation of alpha-amino-3-hydroxy-5-methyl-4-isoxazole-propionic acid receptor (AMPAR) subunits in the developing white matter and cortex in rat (part I) and human (part II). Western blot and immunocytochemistry were used to evaluate the differential expression of AMPAR subunits on glial and neuronal subtypes during the first 3 postnatal weeks in the Long Evans and Sprague Dawley rat strains. In Long Evans rats during the first postnatal week, GluR2-lacking AMPARs were expressed predominantly on white matter cells, including radial glia, premyelinating oligodendrocytes, and subplate neurons, whereas, during the second postnatal week, these AMPARs were highly expressed on cortical neurons, coincident with decreased expression on white matter cells. Immunocytochemical analysis revealed that cell-specific developmental changes in AMPAR expression occurred 2-3 days earlier by chronological age in Sprague Dawley rats compared with Long Evans rats, despite overall similar temporal sequencing. In both white and gray matter, the periods of high GluR2 deficiency correspond to those of regional susceptibility to hypoxic/ischemic injury in each of the two rat strains, supporting prior studies suggesting a critical role for Ca2+-permeable AMPARs in excitotoxic cellular injury and epileptogenesis. The developmental regulation of these receptor subunits strongly suggests that Ca2+ influx through GluR2-lacking AMPARs may play an important role in neuronal and glial development and injury in the immature brain. Moreover, as demonstrated in part II, there are striking similarities between rat and human in the regional and temporal maturational regulation of neuronal and glial AMPAR expression., (Copyright 2006 Wiley-Liss, Inc.)
- Published
- 2006
- Full Text
- View/download PDF
29. NKCC1 transporter facilitates seizures in the developing brain.
- Author
-
Dzhala VI, Talos DM, Sdrulla DA, Brumback AC, Mathews GC, Benke TA, Delpire E, Jensen FE, and Staley KJ
- Subjects
- Animals, Animals, Newborn, Anticonvulsants pharmacology, Bumetanide pharmacology, Diuretics pharmacology, Electroencephalography, Gene Expression Regulation, Developmental, Hippocampus drug effects, Humans, Immunohistochemistry, Infant, Kainic Acid, Membrane Potentials drug effects, Phenobarbital pharmacology, Rats, Rats, Long-Evans, Seizures chemically induced, Seizures physiopathology, Sodium-Potassium-Chloride Symporters genetics, Solute Carrier Family 12, Member 2, Bumetanide therapeutic use, Cerebral Cortex growth & development, Cerebral Cortex physiology, Diuretics therapeutic use, Seizures drug therapy, Sodium Potassium Chloride Symporter Inhibitors
- Abstract
During development, activation of Cl(-)-permeable GABA(A) receptors (GABA(A)-R) excites neurons as a result of elevated intracellular Cl(-) levels and a depolarized Cl(-) equilibrium potential (E(Cl)). GABA becomes inhibitory as net outward neuronal transport of Cl(-) develops in a caudal-rostral progression. In line with this caudal-rostral developmental pattern, GABAergic anticonvulsant compounds inhibit motor manifestations of neonatal seizures but not cortical seizure activity. The Na(+)-K(+)-2Cl(-) cotransporter (NKCC1) facilitates the accumulation of Cl(-) in neurons. The NKCC1 blocker bumetanide shifted E(Cl) negative in immature neurons, suppressed epileptiform activity in hippocampal slices in vitro and attenuated electrographic seizures in neonatal rats in vivo. Bumetanide had no effect in the presence of the GABA(A)-R antagonist bicuculline, nor in brain slices from NKCC1-knockout mice. NKCC1 expression level versus expression of the Cl(-)-extruding transporter (KCC2) in human and rat cortex showed that Cl(-) transport in perinatal human cortex is as immature as in the rat. Our results provide evidence that NKCC1 facilitates seizures in the developing brain and indicate that bumetanide should be useful in the treatment of neonatal seizures.
- Published
- 2005
- Full Text
- View/download PDF
30. Glutamate receptor-mediated oligodendrocyte toxicity in periventricular leukomalacia: a protective role for topiramate.
- Author
-
Follett PL, Deng W, Dai W, Talos DM, Massillon LJ, Rosenberg PA, Volpe JJ, and Jensen FE
- Subjects
- Animals, Calcium metabolism, Cell Death drug effects, Cell Differentiation drug effects, Cell Division drug effects, Disease Models, Animal, Dose-Response Relationship, Drug, Erythroid Precursor Cells metabolism, Erythroid Precursor Cells pathology, Excitatory Amino Acid Agonists pharmacology, Excitatory Amino Acid Antagonists pharmacology, Fructose adverse effects, Gestational Age, Humans, Hypoxia-Ischemia, Brain metabolism, Hypoxia-Ischemia, Brain pathology, Infant, Newborn, Kainic Acid pharmacology, Leukomalacia, Periventricular metabolism, Leukomalacia, Periventricular pathology, Movement Disorders prevention & control, Neuroprotective Agents adverse effects, Neuroprotective Agents therapeutic use, Oligodendroglia drug effects, Oligodendroglia pathology, Quinoxalines therapeutic use, Rats, Receptors, AMPA antagonists & inhibitors, Receptors, AMPA metabolism, Receptors, Glutamate metabolism, Topiramate, Treatment Outcome, Fructose analogs & derivatives, Fructose therapeutic use, Hypoxia-Ischemia, Brain prevention & control, Leukomalacia, Periventricular prevention & control, Oligodendroglia metabolism, Receptors, Glutamate drug effects
- Abstract
Periventricular leukomalacia is a form of hypoxic-ischemic cerebral white matter injury seen most commonly in premature infants and is the major antecedent of cerebral palsy. Glutamate receptor-mediated excitotoxicity is a predominant mechanism of hypoxic-ischemic injury to developing cerebral white matter. We have demonstrated previously the protective effect of AMPA-kainate-type glutamate receptor blockade in a rodent model of periventricular leukomalacia. The present study explores the therapeutic potential of glutamate receptor blockade for hypoxic-ischemic white matter injury. We demonstrate that AMPA receptors are expressed on developing human oligodendrocytes that populate fetal white matter at 23-32 weeks gestation, the period of highest risk for periventricular leukomalacia. We show that the clinically available anticonvulsant topiramate, when administered post-insult in vivo, is protective against selective hypoxic-ischemic white matter injury and decreases the subsequent neuromotor deficits. We further demonstrate that topiramate attenuates AMPA-kainate receptor-mediated cell death and calcium influx, as well as kainate-evoked currents in developing oligodendrocytes, similar to the AMPA-kainate receptor antagonist 6-nitro-7-sulfamoylbenzo-(f)quinoxaline-2,3-dione (NBQX). Notably, protective doses of NBQX and topiramate do not affect normal maturation and proliferation of oligodendrocytes either in vivo or in vitro. Taken together, these results suggest that AMPA-kainate receptor blockade may have potential for translation as a therapeutic strategy for periventricular leukomalacia and that the mechanism of protective efficacy of topiramate is caused at least in part by attenuation of excitotoxic injury to premyelinating oligodendrocytes in developing white matter.
- Published
- 2004
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.